|
|||||
|
|
Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial |
|
| Authors: | R Eastell T Lang S Boonen S Cummings P D Delmas J A Cauley Z Horowitz E Kerzberg G Bianchi D Kendler P Leung Z Man P Mesenbrink E F Eriksen D M Black |
| Institution: | 1. Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, UK 16. Metabolic Bone Centre, Sorby Wing, Northern General Hospital, Herries Road, Sheffield, South Yorkshire, S5 7AU, UK 2. Department of Radiology, University of California, San Francisco, USA 3. Leuven University Centre for Metabolic Bone Diseases and Division of Geriatric Medicine, Katholieke Universiteit Leuven, Leuven, Belgium 4. CPMC Research Institute, University of California, San Francisco, USA 5. INSERM Research Unit 831 and University of Lyon, Lyon, France 6. Department of Epidemiology, University of Pittsburgh, Pittsburgh, USA 7. Savient Pharmaceuticals, New Jersey, USA 8. Argentine Reference Center in Osteoporosis, Hospital Ramos Mejía, Buenos Aires, Argentina 9. Division of Rheumatology, La Colletta Hospital, Genoa, Italy 10. Osteoporosis Research Centre, Vancouver, Canada 11. Faculty of Medicine, Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China 12. Centro TIEMPO, Universidad Favaloro, Buenos Aires, Argentina 13. Novartis Pharmaceuticals Corporation, New Jersey, USA 14. Department of Endocrinology, Aker University Hospital, Oslo, Norway 15. Department of Epidemiology and Biostatistics, University of California, San Francisco, USA |
| Abstract: | SummaryChanges in bone mineral density and bone strength following treatment with zoledronic acid (ZOL) were measured by quantitative computed analysis (QCT) or dual-energy X-ray absorptiometry (DXA). ZOL treatment increased spine and hip BMD vs placebo, assessed by QCT and DXA. Changes in trabecular bone resulted in increased bone strength.IntroductionTo investigate bone mineral density (BMD) changes in trabecular and cortical bone, estimated by quantitative computed analysis (QCT) or dual-energy X-ray absorptiometry (DXA), and whether zoledronic acid 5 mg (ZOL) affects bone strength.MethodsIn 233 women from a randomized, controlled trial of once-yearly ZOL, lumbar spine, total hip, femoral neck, and trochanter were assessed by DXA and QCT (baseline, Month 36). Mean percentage changes from baseline and between-treatment differences (ZOL vs placebo, t-test) were evaluated.ResultsMean between-treatment differences for lumbar spine BMD were significant by DXA (7.0%, p?<?0.01) and QCT (5.7%, p?<?0.0001). Between-treatment differences were significant for trabecular spine (p?=?0.0017) non-parametric test], trabecular trochanter (10.7%, p?<?0.0001), total hip (10.8%, p?<?0.0001), and compressive strength indices at femoral neck (8.6%, p?=?0.0001), and trochanter (14.1%, p?<?0.0001).ConclusionsOnce-yearly ZOL increased hip and spine BMD vs placebo, assessed by QCT vs DXA. Changes in trabecular bone resulted in increased indices of compressive strength. |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |